Holen Sie sich die Stockscreener-App
40.90
4.37%
-1.87
Handel nachbörslich:
41.38
0.48
+1.17%
Schlusskurs vom Vortag:
$42.77
Offen:
$43
24-Stunden-Volumen:
556.15K
Relative Volume:
0.77
Marktkapitalisierung:
$3.06B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-10.35
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
-7.45%
1M Leistung:
+3.39%
6M Leistung:
-24.95%
1J Leistung:
-9.35%
1-Tages-Spanne:
$40.90
$44.22
1-Wochen-Bereich:
$37.92
$45.12
52-Wochen-Spanne:
$33.19
$61.61
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
40.90 | 3.06B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline - MSN
Wells Fargo Maintains Overweight Rating on MRUS but Lowers Price Target | MRUS Stock News - GuruFocus
Merus to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Wells Fargo Adjusts Price Target for Merus (MRUS), Maintains Overweight Rating | MRUS Stock News - GuruFocus
Merus NV reports results for the quarter ended March 31Earnings Summary - TradingView
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (MRUS) Merus NV Posts Q1 Revenue $26.5M - marketscreener.com
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewswire
Financial Health Check: Examining Merus N.V (MRUS)’s Key Ratios - DWinneX
(MRUS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Was Merus N.V (MRUS)’s session last reading good? - uspostnews.com
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus (NASDAQ:MRUS) Position Lifted by Geode Capital Management LLC - Defense World
William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS) - Defense World
Market Watch Highlights: Merus N.V (MRUS) Ends on an Upturn Note at 45.28 - DWinneX
Russell Investments Group Ltd. Decreases Stock Holdings in Merus (NASDAQ:MRUS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merus N.V (MRUS) Is Worth Accumulating At Current Levels - Stocksregister
Daily Progress: Merus N.V (MRUS) Drop -3.19, Closing at 41.83 - DWinneX
MRUS Stock Sees Decline of Approximately -3.22% in Last Five Days - knoxdaily.com
Merus N.V’s Banking’s 100-Day Moving Average at 43.17: Will the Stock Break Through? - investchronicle.com
A stock that deserves closer examination: Merus N.V (MRUS) - uspostnews.com
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - The Manila Times
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting | MRUS Stock News - GuruFocus
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting - Nasdaq
Breakthrough Cancer Drug Outperforms Standard Treatment: Phase 2 Trial Shows Superior Survival Rates - Stock Titan
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals | Libero Quotidiano.it - Libero Quotidiano
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Merus N.V (NASDAQ: MRUS): Getting A Free Pass? - stocksregister.com
Merus’ (MRUS) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Raymond James Financial Inc. Invests $347,000 in Merus (NASDAQ:MRUS) - Defense World
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha
KLP Kapitalforvaltning AS Purchases New Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus stock touches 52-week low at $37.76 amid market challenges By Investing.com - Investing.com South Africa
Merus stock touches 52-week low at $37.76 amid market challenges - Investing.com Australia
HighTower Advisors LLC Has $337,000 Position in Merus (NASDAQ:MRUS) - Defense World
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
How To Trade (MRUS) - news.stocktradersdaily.com
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):